Structural basis for specific inhibition of the deubiquitinase UCHL1

Received: 29 April 2022
Accepted: 15 September 2022
Published online: 10 October 2022

Christian Grethe 1,2,4, Mirko Schmidt 1,2,4, Gian-Marvin Kipka 1,2, Rachel O’Dea 1,2, Kai Gallant 1,2, Petra Janning 3 & Malte Gersch 1,2

Ubiquitination regulates protein homeostasis and is tightly controlled by deubiquitinases (DUBs). Loss of the DUB UCHL1 leads to neurodegeneration, and its dysregulation promotes cancer metastasis and invasiveness. Small molecule probes for UCHL1 and DUBs in general could help investigate their function, yet specific inhibitors and structural information are rare. Here we report the potent and non-toxic chemogenomic pair of activity-based probes GK13S and GK16S for UCHL1. Biochemical characterization of GK13S demonstrates its stereoselective inhibition of cellular UCHL1. The crystal structure of UCHL1 in complex with GK13S shows the enzyme locked in a hybrid conformation of apo and Ubiquitin-bound states, which underlies its UCHL1-specificity within the UCH DUB family. Phenocopying a reported inactivating mutation of UCHL1 in mice, GK13S, but not GK16S, leads to reduced levels of monoubiquitin in a human glioblastoma cell line. Collectively, we introduce a set of structurally characterized, chemogenomic probes suitable for the cellular investigation of UCHL1.
conjugation\textsuperscript{16}, neuronal antioxidation\textsuperscript{17}, and transnitrosylation\textsuperscript{18} have been described.

Specific small molecule inhibitors of UCHL1 have the potential to aid in the mechanistic investigation of its enzymatic function\textsuperscript{19,20}, yet few DUB inhibitors are known, with many of unknown or relatively poor specificity\textsuperscript{21}. Moreover, rational endeavors to improve the potency and specificity of DUB inhibitors are often hampered by the lack of structural information from specific inhibitor:DUB complexes\textsuperscript{22,23} as is also the case for UCHL1. Following the publication of 2- and 3-carboxy-N-cyanopyrrolidines as UCHL1 inhibitors in the patent literature\textsuperscript{24,25}, the Flaherty\textsuperscript{26}, Tate\textsuperscript{27,28}, and Ovaa/Geurink\textsuperscript{29} labs published small molecule activity-based probes for UCHL1. These showed highly potent target engagement in cell lines, covalent inhibition in vitro, and enabled the visualization of UCHL1 activity in live zebrafish. However, some reported compounds showed pronounced cytotoxicity, which is at odds with the viability of many UCHL1 knockout cell lines\textsuperscript{30}. Moreover, various other covalently bound targets were identified which could not be disentangled with the used set of control probes\textsuperscript{32}. In addition, no phenotype in protein abundance following UCHL1 inhibition was detected\textsuperscript{32}.

Here we report the potent and nontoxic UCHL1-targeting 3-carboxy-N-cyanopyrrolidine activity-based probe GK13S from a screen of candidate DUB-targeting nitriles. The crystal structure of UCHL1 in complex with the probe shows UCHL1 locked in a hybrid conformation with some residues in the UCHL1-specific apo and others in the Ubiquitin-bound state. The structure reveals the basis for the inhibitory potency of the probe as well as its exquisite specificity within the highly homologous UCH family of DUBs. We describe how GK13S, together with GK16S, forms a chemogenomic pair of probes which enable the specific investigation of UCHL1 function in cells. Phenocopying the effect that an inactivating mutation of UCHL1 has on the mouse brain, GK13S, but not GK16S, led to the reduction of monoubiquitin levels in the human glioblastoma cell line U-87 MG. Collectively, we introduce a set of

![Image](https://example.com/image.png)

**Fig. 1 | Design and evaluation of an activity-based probe library derived from nitrile-based DUB inhibitors.** a Synthesized activity-based probes (right panel) derived from known inhibitors (left panel), containing a potential nitrile-based warhead (blue) for covalent protein modification and an alkyne handle (green) for bioorthogonal functionalization. See the supporting information for chemical synthesis routes. b Mechanism of thioimidate formation between DUB active site cysteine and small molecule nitrile. c Ubiquitin sulfone (Ub-VS) competition assay. Cell lysates were either incubated with a Ub-VS probe followed by small molecule probe treatment (left path) or treated with the small molecule probe only (right path), in order to indicate whether small molecule probe-modified proteins are DUBs. d Activity-based protein profiling in HEK293 cell lysate with indicated compounds (1µM, 1 h). Proteomes were pretreated with Ub-VS probe where shown. The black arrow indicates a Ub-VS competitive protein target in GK13S- and CG173-treated samples. Uncropped versions of gels are shown in the supplementary information.
structurally characterized, chemogenomic probes suitable for the cellular investigation of UCHL1 function.

Results
A Ubiquitin-probe competition workflow identifies DUB-binding nitriles
Aliphatic nitriles, aryl nitriles and cyanamides of diverse scaffolds have been described as potent covalent inhibitors for various enzymes (Supplementary Fig. 1). We also noted that multiple nitrite-featuring inhibitors for deubiquitinases of the USP and UCH families have been reported, but are generally poorly characterized with regards to their mode of inhibition and their specificity. In an effort to characterize these, we selected a panel of seven structurally diverse parent inhibitors and synthesized corresponding alkynyl-tagged activity-based probes (Fig. 1a and Supplementary Information). We reasoned that these may form covalent thioimidate conjugates with the active site cysteine of deubiquitinases (Fig. 1b) and possibly other cellular proteins and may thus report on their covalent targets in an unbiased manner. In order to evaluate whether these compounds bind deubiquitinases in a complex proteome, we used a Ubiquitin probe competition experiment (Fig. 1c). HEK293 lysate was either treated directly with the compounds or pretreated with the DUB-reactive probe Ubiquitin via sulfone (Ub-VS) followed by small molecule probes. Compound-bound proteins were then visualized through copper-catalyzed click chemistry and samples were analyzed by SDS-PAGE (Fig. 1d). We noted a Ubiquitin-probe competitive band of approx. 30 kDa for the 2- and 3-carboxypyrrolidine probes GK13S and CG173, respectively, which are derived from inhibitors of the DUB UCHL1. This band was also observed in PC-3 cell proteome but absent in proteome from HeLa and MCF-7 cells which are known to have a very low UCHL1 expression level (Supplementary Fig. 2a). Other non-Ubiquitin-probe competitive bands, including a pronounced one with lower molecular weight, indicated additional non-DUB targets for these compounds. Despite the presence of a large number of active DUBs in these sampled cell lines, no other Ubiquitin-probe-competitive bands were observed. CG50R, MS037 and MS023 did not show DUB engagement in this assay, whereas CG017 and CG041 did not show any covalent irreversibly bound proteins at all.

A set of chemogenomic probes for UCHL1
Activity-based probes generally consist of a warhead for covalent target engagement, a specificity element directing target selection and a handle for bioorthogonal functionalization. We focused on compound GK13S, which showed the strongest DUB-probe competitive signal in lysate, and synthesized a systematic set of compounds comprising probes of both stereoisomers (GK13S and GK13R), minimal probes lacking the central aromatic specificity element (GK16S and GK16R) as well as inactive controls lacking the warhead (GK12S and GK12R) (Fig. 2a and Supplementary Information). To assess the specificity of these probes, we treated intact HEK293 cells and visualized covalently bound proteins after 24 h through activity-based profiling (Fig. 2b). While at the high concentration of 10 μM all probes showed binding to a lower molecular weight protein, at 0.1 and 1 μM only GK13S showed a strong signal for a band of ~30 kDa. To confirm that this protein corresponds to the Ubiquitin-probe competitive band observed in lysate, we carried out a reverse Ubiquitin-probe competition experiment. Here intact cells were treated with compounds, their lysate was then incubated with the HA-Ub-VS probe, and active DUBs were visualized by anti-HA western blotting (Fig. 2c). The molecular weight and the strong signal decrease in the HA-Ub-VS competition experiment were consistent with UCHL1 which is the DUB target of the parent inhibitor. As we were concerned about reversibility and incomplete protein modification, we had optimized all steps and identified a click chemistry condition in which recombinantly purified UCHL1 showed near complete modification and established that the protein-probe isothiourea linkage was stable under denaturing conditions (Supplementary Fig. 2d, e). The near complete shift of UCHL1 in the western blot of the GK13S-treated samples (Fig. 2b) suggested that a high degree of modification could be reached in cells.

To identify probe-bound proteins, we used an activity-based protein profiling workflow involving the enrichment of bound proteins via streptavidin and protein analysis by quantitative mass spectrometry (Supplementary Fig. 3a). UCHL1 was the most enriched protein from cells treated with 5 μM of GK13S when compared to DMSO (Fig. 2d), with a logarithmic enrichment factor of 11.5 (equivalent to ~3000-fold) which is in line with the strong signal on the gel (Fig. 2b). At this higher concentration, GK13S also led to the strong enrichment of PARK7 (also known as DJ-1) and the PARK7-homolog C21orf33 (also known as GATD3, a mitochondrial glutamine amidotransferase), as well as several aldehyde dehydrogenases and the Omega-amidase NIT2. Moreover, a large number of weakly enriched proteins was detected, which is consistent with the background observed in the gel-based labeling assay (Fig. 2b). At a lower concentration of 1 μM UCHL1 (with an enrichment factor of 8), PARK7 and C21orf33 were still strongly enriched. Importantly, both PARK7 and C21orf33, but not UCHL1, were also strongly enriched by the minimal probe GK16S, which bound cellular UCHL1 with an enrichment factor of only 3 (Fig. 2d).

We next validated targets through genetic perturbation. siRNA-mediated depletion led to the unambiguous assignment of the upper band labeled by GK13S as UCHL1 and the lower band labeled by both GK13S and GK16R as PARK7 (Fig. 2f). This experiment also clarified that the faint band observed in GK16S-treated samples above PARK7 is not UCHL1, as its intensity is unchanged in the UCHL1-depleted sample while it is consistent with the molecular weight of C21orf33. Overexpression of wild-type UCHL1, but not of its catalytically inactive C90A mutant, confirmed the active center of UCHL1 as the site of labeling by GK13S (Fig. 2g). Likewise, overexpression of wild-type PARK7, but not its catalytic cysteine mutant C160A, led to labeling by all probes tested (Fig. 2h).

Chemogenomic probes denote well-characterized tool compounds for the functional annotation of enzymes in cellular systems. Where a probe which is specific for only a single protein is not available, a comparison of two chemogenomic probes may allow for the specific investigation of a non-overlapping protein target. The comparison of GK13S to GK16S-enriched proteins (Fig. 2e, right panel) suggested that GK13S binds all targets of GK16S but also UCHL1 in addition. A similar pattern was observed for the enantiomer GK13R, which in agreement with the labeling experiment (see Fig. 2b), showed a lower enrichment of UCHL1 than GK13S when compared to either DMSO or the minimal probe (Supplementary Fig. 3b). Collectively, these results suggested that GK13S and GK16S are such a set of chemogenomic probes suitable for the small molecule-mediated investigation of cellular functions of UCHL1.

GK13S potently inhibits recombinant and cellular UCHL1
To characterize the specificity of GK13S for UCHL1 more thoroughly, we analyzed binding and inhibition with recombinant protein. At a probe concentration of 1 μM, GK13S, but not its enantiomer, bound UCHL1 in 1:1 stoichiometry as determined by intact protein mass spectrometry (Fig. 3a). LC-MS measurements at a fixed incubation time of 1 h revealed that the probe and the parent inhibitor have comparable potencies of 50 and 129 nM, respectively, whereas the stereoisomer inhibited about 40-fold worse. Probes lacking the warhead as well as minimal probes did not show any appreciable degree of inhibition (IC_{50} >100 μM), highlighting the need for both the warhead as well as the aromatic specificity element in GK13S for UCHL1 inhibition (Fig. 3b). These data are in agreement with the labeling experiments (Fig. 2b, c) as well as protein mass spectrometry measurements at higher compound concentrations (Supplementary Fig. 4a, b). The
A covalent mode of inhibition was further characterized with a $k_{\text{obs}}/I$ value of GK13S of $681 \text{ M}^{-1} \text{s}^{-1}$ (Fig. 3c), which is in line with the relatively weak electrophilicity of the cyanamide and comparable to other warheads, but still approximately 40-fold larger than for the enantiomer (Supplementary Fig. 5a, b). The binding mode was characterized as covalent-irreversible as inhibition was sustained in a jump-dilution assay (Supplementary Fig. 4c, d), and UCHL1 remained bound to GK13S even after unfolding in 5 M urea and subsequent dialysis (Supplementary Fig. 4e). Consistent with specific recognition of the probe by UCHL1, both the probe as well as the inhibitor, but not the other compounds, led to an increase in protein stability of 6 °C (Fig. 3d). To assess the degree of inhibition of cellular UCHL1, we...
employed a Ub-VS-mediated target engagement assay. Following treatment of HEK293 cells for 24 h with 1 µM of GK13S, near complete inhibition of UCHL1 was observed, whereas other compounds, including the minimal probe, did not inhibit UCHL1 under these conditions. Full inhibition was achieved with 5 µM (Fig. 3e). Since covalent inhibitors act in a time-dependent manner, it is reasonable that the rather large specificity window of GK13S vs GK16S observed in the in vitro assay with 1 h incubation (50 nM vs >100 µM) is reduced when a cellular inhibition with 24 h incubation is assessed (change in log2 enrichment values of 8−3 = 5, equating to >32 fold difference).
This led to the small, but significant detection of UCHL1 by GK16S in the pulldown experiment (Fig. 2e). However, this amount did not equate to a detectable inhibition of the cellular UCHL1 population (Fig. 3e). Consistent with this notion, the in vitro potency difference of GK13S and its enantiomer GK13R (50 nM vs. 2 µM, ~40-fold) did not translate into a similarly wide potency window in a cellular context (change in log2 enrichment values of 2, equating to fourfold difference) (Fig. 3e and Supplementary Fig. 3b). This supports the use of the minimal probe GK16S, but not of the enantiomer GK13R, as a chemogenomic control for GK13S to investigate the specific inhibition of UCHL1.

**Inhibition of UCHL1 by GK13S does not impair cell growth**

As both the 3-carboxyprrolylidine GK13S as well as the 2-carboxyprrolylidine CG173 probes indicated binding to UCHL1 (Fig. 1d), we next compared these compounds in vitro (Supplementary Fig. 4). GK13S, but not GK16S, reduces monoubiquitin in U-87 MG cells and thereby phenocopies the effect of a UCHL1 mutant mouse. a Representative microscopy images of U-87 MG cells were taken 72 h after treatment with 1.25 µM of the indicated compounds (including the control Staurosporine, STS). Effects of the compounds on cell growth and viability were assessed using analysis of confluency (bright-field, BF) and apoptosis (propidium iodide staining, PI). See Supplementary Fig. 7a–d for quantitation. b Cellular activity-based protein profiling of intact U-87 MG cells treated with indicated compounds or DMSO for 1 or 24 h. c Schematic representation of overlapping and individual cellular targets of GK13S and GK16S, supporting their application as chemogenic probes for the investigation of UCHL1. Compare Fig. 2e. d Inhibition of cellular UCHL1. Western blot analysis of endogenous UCHL1 labeled with HA-Ub-VS after treatment of U-87 MG cells with either the indicated compounds or DMSO for 1 or 24 h. e Western blots showing monoubiquitin levels in U-87 MG cells treated with GK13S or GK16S. An additional knockdown of UCHL3 does not aggravate the effect. f Quantification of monoubiquitin intensities upon treatment of U-87 MG cells with DMSO, GK13S, or GK16S (as shown in e). Values correspond to the mean of four or six independent experiments for control or UCHL3 knockdown, respectively. Error values represent the standard error of the mean (s.e.m.). Statistical significance was analyzed using individual one-sample, two-tailed t-tests compared to the mean of ”1” as set for the DMSO-treated samples. "p<0.01 (exact p = 0.0095 for DMSO/GK13S comparison in siScr background and p = 0.0014 for the DMSO/GK13S comparison in the siUCHL3 background); ns, not significant. Uncropped versions of gels and blots are shown in the supplementary information. Source data are provided as a Source Data file.

**Fig. 4 | GK13S, but not GK16S, reduces monoubiquitin in U-87 MG cells and thereby phenocopies the effect of a UCHL1 mutant mouse.**

This led to the small, but significant detection of UCHL1 by GK16S in the pulldown experiment (Fig. 2e). However, this amount did not equate to a detectable inhibition of the cellular UCHL1 population (Fig. 3e). Consistent with this notion, the in vitro potency difference of GK13S and its enantiomer GK13R (50 nM vs. 2 µM, ~40-fold) did not translate into a similarly wide potency window in a cellular context (change in log2 enrichment values of 2, equating to fourfold difference) (Fig. 3e and Supplementary Fig. 3b). This supports the use of the minimal probe GK16S, but not of the enantiomer GK13R, as a chemogenomic control for GK13S to investigate the specific inhibition of UCHL1.

**Inhibition of UCHL1 by GK13S does not impair cell growth**

As both the 3-carboxyprrolylidine GK13S as well as the 2-carboxyprrolylidine CG173 probes indicated binding to UCHL1 (Fig. 1d), we next compared these compounds in vitro (Supplementary...
LG6744443, which has been widely used as a speci-
Observed in HEK293 (Fig. 4b). We included the isatin 
Pattern of bound proteins in U-87 MG was highly similar to that 
protein destabilization45,46, we applied lysine methylation as a crystal-
GK13S and GK16S could be used as chemogenomic probes 
Cpd15825, showed a time- and concentration-dependent inhibition, 
line with the latter, we found that CG173 bound UCHL1 covalently in 
function in cells.

Glioblastoma cells treated with GK13S but not GK16S pheno-
UCHL1 is highly expressed in brain tissue1, and mutations in the UCHL1 
This effect has previously been studied through the overexpression of 
and leads to reduced levels of free monoubiquitin in brain tissue6. 
UCHL1 knockout in many cell lines50 and point to non-UCHL1-related toxicity 
As such, the results collectively suggest that 
not, but not CG173, is suitable for the characterization of UCHL1 
function in cells.

A compound-induced hybrid conformation underlies GK13S-
We next sought to structurally characterize the binding of GK13S to 
we focused on the human glioblastoma cell line U-87 MG. We 
reduced after incubation with GK13S, but not with GK16S (Fig. 4e, f). 
This reduction was unchanged in the background of siRNA-mediated 
reduction of PARK7 (Supplementary Fig. 7e, f) or UCHL3 (Fig. 4e, f), in 
line with the presumed non-redundant function of these two homo-
logous DUBs5. Collectively, these data show that inhibition of UCHL1 by 
UCHL1 in the glioblastoma cell line U-87 MG on a molecular level 
was not successful. As both N- and C-terminal truncation leads to 
protein destabilization45,46, we applied lysine methylation as a crystal-
ization rescue strategy to drive the formation of a crystal form which

Table 1 | Data collection and refinement statistics

| Data collection | UCHL1methylated~GK13S (PDB code: 7ZM0) |
|-----------------|----------------------------------------|
| Beaml ine       | SLS – PXII                              |
| Wavelength      | 1.00 Å                                  |
| Space group     | P 2/a 2/a 2/a                           |
| Cell dimensions | a, b, c (Å)                             |
| a, b, c (Å)     | 101.93, 144.41, 158.25                  |
| Anisotropy correction | yes                               |
| Observed reflections | 421,721                            |
| Unique reflections | 63,622                             |
| Resolution (Å)  | 62.50 – 2.24 (2.54 – 2.24)             |
| Ellipsoid resolution limits (Å) | 3.22 [a*]
| [direction]     | 2.70 [b*]                              |
| Rmerge          | 0.053 (0.457)                           |
| Rmax            | 0.057 (0.499)                           |
| R(free)         | 18.0 (3.4)                              |
| CC1/2           | 1.000 (0.917)                           |
| Spherical Completeness (%) | 56.3 (10.7)                      |
| Ellipsoid Completeness (%) | 95.2 (83.0)                        |
| Redundancy      | 6.6 (6.3)                               |
| Wilson B (Å2) [direction] | 111 [a*]
|                 | 71 [b*]                                |
|                 | 42 [c*]                                |
| Refinement      | Copies/a.s.u.                           |
|                 | 10                                       |
| Resolution (Å)  | 2.24 Å                                  |
| No. reflections | 63,574                                  |
| R_obs / R_free (%) | 24.0 / 28.8                        |
| No. atoms       | 16,195                                  |
| Protein         | 15,574                                  |
| Ligand          | 290                                     |
| Water           | 331                                     |
| B factors (Å2)  | 62.7                                    |
| Protein (Å2)    | 62.9                                    |
| Ligand (Å2)     | 69.7                                    |
| Water (Å2)      | 47.9                                    |
| R.m.s.d.        | 0.003                                   |
| Bond angles (%) | 0.51                                    |
| Ramachandran (favored/allowed/ outlier) (%) | 98.2/98.2/0%
| Clashscore      | 4.8                                     |
| Rotamer outliers (%) | 1.6                              |

The dataset was collected from a single crystal. Values in parentheses are for the highest-
resolution shell.
a.s.u. asymmetric unit, R.m.s.d. root mean square deviations.

is compatible with compound binding. Following near complete 
methodylation, we complexed methylated UCHL1 with GK13S (Supple-
mentary Fig. 8a) and identified a crystallization condition from which 
the structure of UCHL1 in complex with GK13S was solved to 2.24 Å 
resolution after anisotropic scaling (Table 1). The asymmetric unit 
contained ten copies with a well-defined density of the ligand (in eight 
copies for warhead, pyrrolidine, central amide, imidazole and phenyl
ring and in two copies up to the imidazole; the peripheral amide and 
the alkyl chain do not adopt a defined position in all copies)
Supplementary Fig. 8b–d). Superposition of all copies revealed identical positioning of the ligand (Supplementary Fig. 9a–c).

GK13S is bound covalently to the catalytic cysteine Cys90 through an isothiourea with its cyanamide warhead and occupies a shallow cleft that, during catalysis, guides the Ubiquitin C-terminal LRGG peptide to the active site (Fig. 5a–c). The isothiourea is stabilized by the oxyanion hole formed by Gln84 and Gly87, with the residues of the catalytic triad in hydrogen bonding distance (Fig. 5d).

The central amide as well as the imidazole ring of GK13S engage UCHL1 on both sides of the cleft with hydrogen bonds to the backbone of Phe160, Met6 and Ile8, which also coordinate the backbone of the Ubiquitin C-terminal peptide (Fig. 5e–g). Superposition revealed that GK13S features hydrogen bonding acceptors and donors of similar geometry as Ubiquitin and that the phenyl ring of GK13S mimics the hydrophobic side chain of Leu73 of Ubiquitin which is recognized by Phe160 (see black arrows in Fig. 5g).

Superposition of the structure of compound-bound UCHL1 with apo (Supplementary Fig. 9d) and Ubiquitin-bound UCHL1 (Fig. 5b, c) by GK13S are indicated with black arrows (a hydrogen bond acceptor, a hydrogen bond donor and the hydrophobic Leu73 side chain).
structures showed overall high similarity, yet closer inspection of the compound binding site revealed characteristic differences (Fig. 5h). The side chains of some residues, in particular of Phe162, Ile8, and Leu52, in the compound-bound structure displayed the same arrangement as observed in apo UCHL1, creating a narrow hydrophobic pocket which surrounds the pyrrolidine of GK13S and accounts for the observed preference for the $S$-configured stereoisomer. Conversely, the side chains of His161 and Phe160 and the secondary structure elements $\beta$3 and $\beta$2 showed a conformational change upon Ubiquitin binding are indicated with arrows. Indicated Flag-UCHL3 constructs with mutations introducing a GK13S binding site were overexpressed in HEK293 cells. Cells were treated with a compound where indicated, and GK13S-bound proteins were visualized by in-gel fluorescence. Uncropped versions of gels and blots are shown in the supplementary information. Sequence alignment of human Ubiquitin C-terminal Hydrolase (UCH) family members. Secondary structure assignments are based on the UCHL1~GK13S structure. Black arrows indicate residues mutated in e. For a full sequence alignment, see Supplementary Fig. 10a. 

Fig. 6 | Structural basis for specific inhibition of UCHL1. a Average distance alignment and schematic representation of domain architecture of human UCH family deubiquitinases. Boundaries of bacterially expressed UCH catalytic domain constructs are given. ULD, UCH37-like domain. 

b Ubiquitin rhodamine cleavage assay of indicated recombinant UCH DUBs, preincubated with GK13S dilutions for 1h. Data points are shown as mean ± standard error from $N = 2$–5 independent experiments, as indicated in the figure. Source data are provided as a Source Data file. c Superposition of UCHL1-GK13S with apo UCHL1 (pdb: 2ETL) and apo UCHL3 (pdb: 1UCH) and close-up view of the binding pocket. Labeled residues are shown as sticks. d Superposition of the equivalent to the compound binding pocket in apo UCHL3 and UCHL3-Ub-VME (pdb: 1XD3). The Ubiquitin C-terminus is shown in cartoon representation. Residues undergoing a conformational change upon Ubiquitin binding are indicated with arrows. e Indicated Flag-UCHL3 constructs with mutations introducing a GK13S binding site were overexpressed in HEK293 cells. Cells were treated with a compound where indicated, and GK13S-bound proteins were visualized by in-gel fluorescence. Uncropped versions of gels and blots are shown in the supplementary information. 

close-up view of the Ubiquitin C-terminus is shown in cartoon representation. Residues undergoing a conformational change upon Ubiquitin binding are indicated with arrows. Indicated Flag-UCHL3 constructs with mutations introducing a GK13S binding site were overexpressed in HEK293 cells. Cells were treated with a compound where indicated, and GK13S-bound proteins were visualized by in-gel fluorescence. Uncropped versions of gels and blots are shown in the supplementary information. Sequence alignment of human Ubiquitin C-terminal Hydrolase (UCH) family members. Secondary structure assignments are based on the UCHL1~GK13S structure. Black arrows indicate residues mutated in e. For a full sequence alignment, see Supplementary Fig. 10a. 

g Close-up view of the binding pocket of UCHL1-GK13S (left panel) and superposition with full-length UCHL5 (pdb: 3RIH), the catalytic domain of UCHL5 (pdb: 3RII) and UCHL5 in co-complex with an inhibitory fragment of INO80G (pdb: 4UF5) (from left to right).
Fig. 7 | A potential hotspot for DUB ligandability across families. a–d Selection of structurally characterized DUB inhibitors of USP1450 (a), USP744,51 (b), SARS PL,pro52 (c), and UCHL1 (d). Shown are the structures of the compounds, a close-up view of their binding pockets from co-crystal structures, and overlays of these co-crystal structures with Ubiquitin-bound structures of the respective DUBs. The Leu73 position is indicated with black arrows. The chemical moieties of the inhibitors that occupy the position of Leu73 of Ubiquitin are highlighted with a beige background.
the imidazole ring of GK13S, yet Phe160 in the apo conformation would be unable to perform π–π-stacking with the phenyl ring of the compound. We validated the importance of these residues through overexpression of mutated forms of UCHL1 in HEK293 cells and subsequent activity-based protein profiling with GK13S. This led to drastic decreases in fluorescence, indicating reduced compound binding to mutated UCHL1 proteins (Fig. 5k). Of note, the binding site of GK13S to UCHL1 is distinct from that of a peptide fluoromethyl ketone\(^{46}\), which was soaked into UCHL1 apo crystals and engages hydrophobic residues in neighboring copies within the crystal lattice, but not in the Ubiquitin binding cleft near the modified cysteine (Supplementary Fig. 9e–g).

**Structural basis for specific inhibition of UCHL1**

Our structure revealed that GK13S mimics the commonly recognized Ubiquitin C-terminal peptide through hydrogen bonding and hydrophobic interactions, prompting the question of why the probe is specific for UCHL1 in the complex proteome (Fig. 2e). The UCH family of DUBs comprises four members, including UCHL3 as the closest homolog of UCHL1, as well as proteasome associated UCHL5 and the tumor suppressor BAP1 with the latter two featuring extensions C-terminal to the catalytic domain with regulatory functions (Fig. 6a)\(^{2,3}\). Assays with purified catalytic domains of these proteins confirmed the exquisite specificity of GK13S for UCHL1 over the other UCH family members (Fig. 6b and Supplementary Fig. 9b).

Structural superposition of compound-bound UCHL1 with apo UCHL3\(^{31}\) revealed that UCHL3 adopts a different conformation in its N-terminal residues (Fig. 6c), and also a distinct conformational transition occurs upon Ubiquitin binding (Fig. 6d). In particular, Leu9 of UCHL3 (corresponding to Met6 in UCHL1) sterically precludes binding of GK13S to its apo conformation, and the lack of a large hydrophobic side chain of Ala11 of UCHL3 (corresponding to Ile8 in UCHL1) prevents the formation of a hydrophobic pocket for the pyrrolidine ring. Moreover, Leu166 in UCHL3 (corresponding to Phe160 of UCHL1) would form a different environment for the phenyl ring of GK13S. This analysis suggested that the aromatic side chain of Phe160 and the UCHL1-specific apo conformation triggered by Ile8 establish the basis for specificity of GK13S to UCHL1 (Supplementary Fig. 9i,j). To test this hypothesis, we overexpressed UCHL3 with point mutations in these residues exchanged to the corresponding UCHL1 amino acids in HEK293 cells and assessed their probe binding (Fig. 6e,f). While A11I and L168F alone showed weak binding to GK13S, the double-mutant of UCHL3 showed binding to GK13S similar to that of endogenous UCHL1. Consistently, recombinantly purified UCHL3 with the double-mutation could be inhibited by GK13S, albeit with lower potency than wild-type UCHL1, suggesting that the UCHL1-specific, inhibition-competent conformation can at least partially be triggered by these mutations in UCHL3 (Supplementary Fig. 10a–c). In contrast, all UCHL3 variants were inhibited by the non-specific alkylation agent iodoacetamide with similar potency, demonstrating that the binding of GK13S to UCHL1 enzymes is not primarily driven by the chemical reactivity of the catalytic cysteine (Supplementary Fig. 10d).

The activity of UCHL5 is allosterically regulated by conformational changes upon engagement of the proteasome as well as regulatory complexes\(^{1}\). Both full-length and catalytic domain structures of UCHL5 in their apo states as well as a complex with INO80G showed an occupied cleft incompatible with GK13S binding. Moreover, the substitution of Ile8 in UCHL1 for a smaller and polar serine (Ser13 in UCHL5 or Ser10 in BAP1) likely prevents hydrophobic coordination of the pyrrolidine as the space is occupied by phenylalanine (Fig. 6g). These differences can rationalize why GK13S does not bind to UCHL5 and BAP1.

Taken together, our data firmly establish that (i) a UCHL1-specific apo conformation, (ii) subtle differences in the binding pocket on both sides of the catalytic cleft within the UCH family of DUBs as well as (iii) conformational plasticity underly the specific inhibition of UCHL1 by GK13S. They further demonstrate that GK13S is specifically recognized by UCHL1, and that this specificity is not the result of increased reactivity or abundance of UCHL1.

**Discussion**

Signaling through ubiquitination requires tight control of deubiquitinasen as high constitutive DUB activity may preclude the buildup of specific Ubiquitin modifications. Multiple layers of regulation controlling DUB activity have been described modulating DUB abundance, localization, and catalytic activity\(^{6}\). Conformational plasticity, i.e., active and inactive conformations, can structurally enable such regulation and has been reported for multiple deubiquitinases, including UCHL1. While its apo conformation displays an unaligned catalytic triad and a partially occupied binding cleft\(^{16}\), engagement of the globular part of Ubiquitin facilitates a conformational change which aligns the triad and widens the cleft making it competent for guiding the Ubiquitin C-terminal RRGG peptide to the catalytic cysteine\(^{1}\). While for its homolog UCHL5 activating as well as inhibitory regulatory proteins have been described\(^{2}\), it is unclear whether similar proteins exist for UCHL1, which could allosterically control its conformational state.

We here show that this conformational plasticity underlies the specific inhibition of UCHL1 by the 3-cyanoxy-N-cyanopyrrolidine probe GK13S, which locks the enzyme in a hybrid conformation of apo and Ubiquitin-bound states. GK13S mimics the C-terminal LRGG peptide of Ubiquitin through key hydrogen bonding and hydrophobic interactions yet achieves specificity through positioning its pyrrolidine in a pocket unique to the apo conformation of UCHL1. Structural information for specific inhibitors with cellular potency is available only for very few other DUBs\(^{22,44}\), including USP14\(^{45}\), USP744,51, and the coronavirus protease PLpro\(^{46}\). It is noteworthy that in these cases, despite the entirely different DUB fold inhibitors are engaged where the Leu73Arg74 dipeptide of Ubiquitin is recognized, suggesting a general hotspot for DUB ligandability across families (Fig. 7a–d).

 Whereas other DUB inhibitors stabilize either the active or the inactive conformation\(^{22,44}\), the structure of UCHL1 in complex with GK13S highlights that also new (hybrid) compound-induced conformations can be exploited by inhibitors. This principle makes it likely that specific inhibitors will be found for other DUBs which, while sharing their substrate Ubiquitin, may differ in their conformational flexibilities. The structure rationalizes the need for the warhead and the chemical characteristics of its specificity element and explains the observed stereo preference. Moreover, it will form the basis for rational efforts to improve potency and selectivity in further generations of UCHL1 inhibitors.

In addition to UCHL1 as its main protein target, GK13S also binds to PARK7 and the PARK7 family member C21orf33. These targets, as well as the aldehyde dehydrogenases, ISOC1 and NIT2 observed for the control probe GK16S, are in agreement with previous target ID experiments on related 3-carboxy-N-cyanopyrrolidines\(^{27–29}\). Non-UCHL1 proteins are also bound by the minimal probe GK16S, which lacks the specificity element, features an IC\(_{50}\) for UCHL1 of >100 µM, leads to a much-reduced enrichment in pulldown assays, and, in contrast to GK13S does not inhibit cellular UCHL1. Consistent with the covalent mode of action, we find a reduced specificity window when comparing in vitro potencies to cellular potencies. The large difference in the potencies of GK13S and GK16S both in vitro and in cells allowed comparing in vitro potencies to cellular potencies. The large difference in the potencies of GK13S and GK16S both in vitro and in cells allowed comparing in vitro potencies to cellular potencies. The large difference in the potencies of GK13S and GK16S both in vitro and in cells allowed comparing in vitro potencies to cellular potencies. The large difference in the potencies of GK13S and GK16S both in vitro and in cells allowed comparing in vitro potencies to cellular potencies. The large difference in the potencies of GK13S and GK16S both in vitro and in cells allowed comparing in vitro potencies to cellular potencies.
GK16S (Supplementary Fig. 11), revealing that 1,3-carboxycyanopyrrolidines and glutamine share a similar size and connectivity between their electrophilic center and a carbonyl moiety. Future studies comparing cyanamides of different geometries will need to clarify their target scope, substrate recognition and cellular occupancies of these and other targets. The fact that 3-amino-N-cyanopyrrolidines have recently been described as inhibitors for USP30 and JOSD1 makes it likely that an expanded set of chemogenomic probes could be assembled to specifically investigate the functions of these DUBs despite the cross-reactivity of some of the scaffolds.

Our data establish that both GK13S and GK16S do not impair cell growth in HEK293 and U-87 MG cells under conditions that lead to complete inhibition of UCHL1 by GK3S. This demonstrates that the high toxicity of the 2-carboxy-N-cyanopyrrolidine CG173 as well as related compounds is unrelated to UCHL1. CG173 binds twice to UCHL1 in vitro, consistent with modification of both catalytic Cys90 and hyperreactive CysL52. Counterintuitively, CG173 shows weak and decreasing inhibition of cellular UCHL1 with longer incubation times. Whether this behavior and the toxicity are a general feature of the substituted 2-carboxy-N-cyanopyrrolidine scaffold remains to be investigated from larger compound libraries.

Despite intense research effort, mechanistic links that reconcile the various catalytic activities of UCHL1 with regulated cellular phenotypes are scarce. We concur with others who have called the use of compound LDN-57444 as a specific and effective inhibitor of cellular UCHL1 into question. Genetic models have linked UCHL1 to neurodegeneration and reported reduced levels of monoubiquitin in brain tissue of a UCHL1 mutant mouse, which was previously studied with overexpressed mutant UCHL1 in a monkey cell line. We reconstituted the effect in a human glioblastoma cell line through controlled small-molecule-mediated inhibition of endogenous UCHL1. This not only validated our chemogenomic pair of probes for the investigation of UCHL1, but also established U-87 MG cells as a suitable model system for UCHL1-dependent phenotypes, such as the observed disturbance in ubiquitin homeostasis.

As GK13S both binds the catalytic cysteine and blocks the engagement of Ubiquitin, it will not only abrogate the hydrolase activity but also other activities. We can, therefore, not conclude whether the reduced levels of monoubiquitin come e.g., from reduced hydrolytic processing of substrates or from reduced binding/ buffering of free Ubiquitin. It is tempting to speculate that the large amounts of UCHL1, through regulation of the concentration of available free Ubiquitin, may act as a molecular rheostat which would determine global ubiquitination activities. These mechanisms and the link to neurodegeneration remain to be investigated.

As both probes are equipped with a bioorthogonal handle, their target spectrum in additional cell lines can readily be evaluated as a control experiment. In addition, their covalent nature will facilitate Ubiquitin-probe-based UCHL1 target engagement experiments to ensure that observed effects track with UCHL1 inhibition. We are thus convinced that the here described set of nontoxic, chemogenomic probes for UCHL1 will not only enable the structure-guided improvement of UCHL1 inhibitors but will also be directly and broadly applicable in the dissection of its cellular functions. Moreover, our structure suggests a general hotspot of ligandability within DUBs of different families and that specificity of inhibitors for other DUBs may be achieved through the exploitation of conformational flexibility underlying the endogenous regulation of DUB activity.

Methods

Chemical synthesis

See the supplementary information for compound synthesis and characterization data.

Cloning and constructs

Human UCHL1 (UniProt: P09936, residues: 1-223), UCHL3 (UniProt: P15374, residues: 1-230), UCHL5 (UniProt: Q9Y5K5, residues: 1-228), BAPI (UniProt: Q92560, residues: 1-235), and PARK7 (UniProt: Q99497, residues: 1-189) sequences were cloned from cDNA templates for bacterial expression into the pOPIN-B vector (for UCHL1 and PARK7, N-terminal His6-3C tag, an additional GS linker was used for UCHL1) or into the pOPIN-K vector (for UCHL3, UCHL5, and BAPI, N-terminal His6-GST-3C tag) and into the pOPIN-E vector for mammalian cell transfection (with an N-terminal Flag-GS tag and no C-terminal tag) using the In-Fusion HD Cloning Kit (Takara Clonetech). Site-directed mutagenesis was carried out by splicing-by-overlap extension PCR using Phusion Polymerase (New England BioLabs).

Protein expression and purification

For bacterial expression of proteins, Rosetta2(DE3) pLacI cells were transformed with the respective vector. Overnight cultures were diluted 1:100 into 2xTY medium, which was supplemented with appropriate antibiotics, and cultures were grown shaking at 37 °C. When an A600 of 0.8 was reached, cultures were cooled to 18 °C, isopropyl-β-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM and cultures were grown overnight. Cells were harvested by centrifugation at 4 °C and stored at −80 °C. The pellets were thawed, resuspended in lysis buffer (50 mM H2NaPO4, 300 mM NaCl, 20 mM imidazole, pH 8.0, supplemented with lysozyme and DNase, and with Complete protease inhibitors for UCHL5 and BAPI) and lysed by sonication on ice for 5 min. The lysates were cleared by centrifugation at 22,000g for 30 min at 4 °C and sterifie filtered. The clear lysate was then passed through a 5 mL HisTrap column (GE Healthcare), preequilibrated with buffer A (50 mM H2NaPO4, 300 mM NaCl, 20 mM imidazole, pH 8.0), using an AKTA Pure System (GE Healthcare). The protein was then eluted into buffer B (50 mM H2NaPO4, 300 mM NaCl, 500 mM imidazole, pH 8.0). Protein-containing fractions were pooled and concentrated. For UCHL1 and PARK7, GST-3C protease was added and the sample was dialyzed into buffer C (20 mM Tris pH 8.0, 100 mM NaCl, 4 mM DTT) overnight. These proteins were further purified by size exclusion chromatography using a HiLoad 16/600 Superdex 75 pg column (GE Healthcare) with buffer C. PARK7 was dialyzed subsequently into buffer D (20 mM KH2PO4 pH 7.0 and 5 mM DTT). For UCHL3, UCHL5, and BAPI, His6-3C protease was added and the sample was dialyzed into a lysis buffer. Dialyzed samples were then passed through a pre-equilibrated HisTrap column and the eluate was diluted into a low salt buffer (25 mM Tris pH 8.5, 50 mM NaCl, 4 mM DTT). These proteins were further purified by anion exchange chromatography on a ResQ column (GE Healthcare) by elution into a high salt buffer (25 mM Tris pH 8.5, 500 mM NaCl, 4 mM DTT) over 20 column volumes. Fractions containing pure protein were pooled, concentrated, and buffer exchanged into buffer C + 5% glycerol and protein concentrations were measured by UV absorbance on a Nanodrop 2000.

Lysine methylation of UCHL1

Methylation of primary amines in UCHL1 was achieved by adding 600 µL of freshly prepared dimethylamine-borane complex (1 M) and 1.2 mL formaldehyde solution (1 M) to 30 mL of UCHL1 (1 mg/mL) in buffer E (50 mM Hepes pH 7.5, 250 mM NaCl). After incubation for 2 h at 4 °C, 600 µL of dimethylamine-borane complex (1 M) and 1.2 mL formaldehyde solution (1 M) were added and the incubation continued for an additional 2 h. Then 300 µL of dimethylamine-borane complex (1 M) was added and the reaction was incubated overnight at 4 °C. The next day precipitated protein was removed by centrifugation. After concentrating to a final volume of 1.5 mL, the protein was purified by size exclusion chromatography into buffer F (50 mM Tris pH 7.5, 200 mM NaCl). The
protein was concentrated at 17 mg/mL and directly used for crystallization experiments.

Co-crystallization
Crystallization was carried out in 96-well sitting-drop vapor diffusion plates in MRC format (Molecular Dimensions) at 18 °C and set up using a mosquito HTS robot (TTP Labtech). Typical drop ratios of 200 nL + 200 nL and 400 nL + 400 nL (protein solution + reservoir solution) were used for coarse screening and fine screening, respectively. For co-crystallization experiments, methylated UCHL1 (meUCHL1, 17 mg/mL) was reprecipitated with 1.2 equivalents of GK13S. Covalent adduct formation was confirmed by intact protein mass spectrometry. After buffer exchange into buffer G (20 mM Tris pH 8.0, 100 mM NaCl), meUCHL1-GK13S was concentrated at 30 mg/mL and crystallized in 2.3 M ammonium sulfate, 110 mM K3PO4, and 90 mM K2HPO4 as hexagonal prisms (120 × 45 × 45 μm). Cryoprotection was achieved by placing the crystal for a few seconds into 3 M sodium malonate pH 7.0 with 1 mM GK13S, followed by immediate vitrification in liquid nitrogen.

Data collection, structure solution and refinement
Diffraction data were collected at 100 K at the Swiss Light Source (SLS, Villigen-PSI, Switzerland) on beamline PXII. The dataset leading to the structure of meUCHL1-GK13S was integrated using Dials and anisotropically scaled using the STARANISO web server. The structure was solved by molecular replacement using MR Phaser and the apoprotein as a search model (pdb 2ETL). Model building using Coot and refinement with PhenixRefine yielded the final structure. Data collection, anisotropy correction and refinement statistics are given in Table 1. Data have been deposited with the protein data bank under accession code 7ZMO.

Ub-Rhodamine assay
Reactions were performed in black 384 well low volume non-binding surface plates (Greiner 784900) in a final volume of 20 μL. DUBs were diluted in reaction buffer H (20 mM Hepes pH 8.0, 50 mM NaCl, 0.05 mg/ml BSA) to a 4x stock (final concentrations: UCHL1: 0.06 mM; UCHL3: 0.25–0.5 mM; UCHL5: 0.01 mM; BAP1: 0.01 mM). DUBs were mixed in a 1:1 ratio with 4x compound dissolved in reaction buffer (final DMSO concentration: 0.1–1%). To each well was added 10 μL of DUB-compound solution in triplicates, followed by 1 h incubation time. Reactions were initiated by the addition of 10 μL Ub-Rhodamine 110 (Biomol, final concentration: 50 nM, diluted into reaction buffer supplemented with 5 mM DTT) and fluorescence (excitation = 492 nm, emission = 525) was read on a Tecan Spark plate reader with Tecan SparkControl software for 1 h in 1.5 min intervals at room temperature. Biochemical IC50 values were calculated using GraphPad Prism. The experiment with iodoacetamide (Supplementary Fig. 10d) was carried out with a final concentration of 5 mM DTT in buffer H.

\[ k_{obs}/[I] \] kinetic assay
Reactions were performed in 384 well plates as above. Compound (5 μL of a 4x stock in reaction buffer H supplemented with 2.5 mM TCEP; varying final concentrations ranging from 78 nM to 200 μM) and Ub-Rhodamine 110 (5 μL of a 4x stock in buffer H supplemented with 2.5 mM TCEP; final concentration: 50 nM) were mixed in a 1:1 ratio. To each well was added 10 μL of UCHL1 (2x stock in buffer H supplemented with 2.5 mM TCEP; final concentration: 0.06 mM) and fluorescence was recorded as described above. The kinetic constant \( k_{obs} \) was obtained from fitting the curve with a one-phase association function to

\[ Y(t) = Y_0 + (A - Y_0) \cdot (1 - e^{-k_{obs} \cdot t}) \]

wherein \( Y(t) \) denotes the fluorescence change over time \( t \), starting at the initial fluorescence \( Y_0 \) and going up to a plateau \( A \). The observed rate constant \( k_{obs} \) was plotted over the inhibitor concentration. Linear regression of the corresponding curve resulted in \( k_{obs}/[I] \)-values as slope, which enabled comparison of covalent inhibitor potencies.

Intact protein mass spectrometry
The recombinant protein was diluted to a final concentration of 3 or 0.8 μM in buffer I (20 mM Hepes pH 8.0, 50 mM NaCl) and treated with DMSO/compound to result in a final concentration of 10 or 1 μM, respectively. Followed by incubation of 1 h at room temperature, the samples were either run through a MassPrep Online Desalting 2.1 mm × 10 mm cartridge (Waters, flow rate 0.5 mL/min, runtime 7 min, column temperature 30 °C) or an AdvanceBio DesaltingRP 2.1 mm × 12.5 mm cartridge (Agilent, flow rate 0.4 mL/min, runtime 6 min, column temperature 32 °C) with solvents A = HPLC-grade H2O + 0.1% TFA or formic acid and solvent B = HPLC-grade acetonitrile + 0.1% TFA or formic acid as mobile phases, respectively. A gradient from 20–90% solvent B (MassPrep Online Desalting cartridge) or 5–95% solvent B (AdvancedBio DesaltingRP) was programmed. The samples were either analyzed on a Velos Pro Dual-Pressure Linear Ion Trap mass spectrometer (ThermoFisher, with Xcalibur software), equipped with an electro spray ion source in positive mode (capillary voltage 5 kV, desolation gas flow 40 L/min, temperature 275 °C) or on an Agilent 1260 Infinity system (Agilent, with OpenLab software), equipped with an electro spray ion source in positive mode (capillary voltage 4 kV, desolation gas flow 80 L/min, temperature 350 °C). Spectra were deconvoluted with ProMass (Enovatia).

Thermal shift assay
Reactions were performed in white 96-well PCR plates (Bio-Rad). UCHL1 was diluted in thermal shift buffer (1x PBS, 5 mM DTT) to a 4x concentration of 4 μM. The protein was then mixed with 4x compound dissolved in thermal shift buffer in a 1:1 ratio. To each well was added 20 μL of DUB-inhibitor solution, followed by 1 h incubation time. To each well was then added 20 μL 4x SYPRO Orange in thermal shift buffer. After sealing the plates with a transparent film, thermal denaturation (gradient: 20–90 °C, Increment: 0.3 °C; hold for 5 s before read) was performed and monitored by a Bio-Rad Connectycler.

Jump-dilution assay
Reactions were performed in similar 384 plates as above in a final volume of 20 μL. UCHL1 was diluted in reaction buffer H (20 mM Hepes pH 8.0, 50 mM NaCl, 5 mM Hepes, 0.1 mg/ml BSA) to a concentration of 6 nM (final concentration in well 0.06 nM). To this was added 625 nM GK13S or DMSO and the mixture was incubated for 2 h. Parts of this solution were diluted at 1:50 at different time points with buffer H. All samples were then diluted 1:2 with 100 nM Ub-Rh (buffer H, final concentration in well 50 nM) and fluorescence was recorded as described above. Half-life time was obtained by fitting the curve with a one-phase decay function to

\[ Y(t) = A + (Y_0 - A) \cdot e^{-k_{obs} \cdot t} \]

wherein \( Y(t) \) denotes the fluorescence change over time \( t \), starting at the initial fluorescence \( Y_0 \) and decreasing to a plateau \( A \). The half-life time displays the time at which the curve reaches 50% of the plateau.

Dialysis dilution assay
UCHL1 (20 μM) was either incubated with DMSO or GK13S (40 μM) for 1 h to achieve near complete inhibition, and then diluted 1:5 with either PBS or 5 M of urea. A hole was cut into the lid of the L5 mL Eppendorf tubes and a SnakeSkin dialysis tubing membrane (3.5 K MWCO) was fit between the lid and the tube. The tubes were turned upside down, fastened in a floating rack and dialyzed against 11 of PBS overnight.
Cells were subsequently processed as described below. Added dropwise to the cells. Twenty-four hours after transfection, cells medium. Both solutions were combined, incubated for 5 min, and µL OPTI-MEM supplemented with 10% fetal bovine serum (FBS) and 2% penicillin-streptomycin. PC-3 cells were cultivated in F-12K Nut Mix media supplemented with 10% FBS and 2% penicillin-streptomycin. Cells were tested negative for mycoplasma contamination.

**Transfection**

HEK293 cells (7 × 10⁵/well) were seeded in six-well plates and cultivated for 24 h. PEI transfecting reagent (Polysciences) was preincubated for 15 min with the vectors in a 200 µL OPTI-MEM medium. Cells were then transfected with vectors and incubated for 24 h. Following the treatment with either compounds or DMSO in fresh media for an additional 24 h, cells were processed as described below. For knockdown of UCHL1 and PARK7, siRNA (scrambled: siGENOME Non-Targeting siRNA Control Pools, D-001206-13-05; UCHL1 smart pool: siGENOME Human UCHL1 siRNA, M-004309-00-0005; PARK7 smart pool: siGENOME Human PARK7 siRNA, M-005984-00-0005; UCHL3 smart pool: siGENOME Human UCHL3 siRNA, M-006592-02-0005) were obtained from Dharmacon. Cells were seeded as described above. About 2 µL of 10× µM siRNA was diluted in a 100 µL OPTI-MEM medium. Additionally, 6 µL RNAiMAX (Thermo Fisher) were diluted with 100 µL OPTI-MEM medium. Both solutions were combined, incubated for 5 min, and added dropwise to the cells. Twenty-four hours after transfection, cells were treated with the compounds or DMSO in fresh media for 24 h. Cells were subsequently processed as described below.

**Cell growth and viability assay**

HEK293 cells (5 × 10⁵/well) or U-87 MG cells (5.5 × 10⁵/well) were seeded in 10 cm dishes and grown to 90% confluence. The medium was aspirated, cells were washed with ice-cold PBS, treated with 600 µL ABP lysis buffer (1% (v/v) IGEPAL, 50 mM Tris, 150 mM NaCl, 5% glycerol, pH 8, Complete protease inhibitor cocktail), and incubated on ice for 15 min. The lysed cells were scrapped off the dish, cleared by centrifugation, and the protein concentration was determined using the Incucyte S3. Bright-field and red fluorescent images were automatically captured at 1 or 2 h intervals for 72 h with 10x magnification. The confluency of cells and the number of PI-positive cells was determined using the Incucyte masking program.

**Activity-based protein profiling in the lysate**

Cells (4 × 10⁷) were seeded in 10 cm dishes and grown to 90% confluence. The medium was aspirated, cells were washed with ice-cold PBS, treated with 600 µL ABP lysis buffer (1% (v/v) IGEPAL, 50 mM Tris, 150 mM NaCl, 5% glycerol, pH 8, Complete protease inhibitor cocktail), and incubated on ice for 15 min. The lysed cells were scrapped off the dish, cleared by centrifugation, and the protein concentration was determined via a Bradford assay. The cell lysate was diluted to a protein concentration of 2–4 mg/mL with ABP lysis buffer, split in half, and one-half treated with HA-Ub-VS (1 µM final concentration, 37°C, 30 min). Each compound was diluted to a 2x concentration in PBS buffer from a 10 mM stock in DMSO (final concentration: 1 µM). Then each compound dilution or a DMSO dilution was mixed with cell lysate and incubated for one hour at room temperature. Afterwards, 1 µL of each click reagent (final concentration of 0.5 mM CuSO₄·5 H₂O, 1 mM BTAA, 4 mM 5/6-TAMRA-Azide-Biotin (Jena Bioscience), 5 mM sodium ascorbate, each from 100x stocks) were added to each sample, followed by an incubation period of one hour at room temperature with protection from light. The samples were resolved by SDS-PAGE using a 4–12% Bis-Tris gel (Invitrogen, NuPAGE) with MES SDS running buffer for 50 min at 180 V. Fluorescence was read out using the Alexa664 (λex/em = 520–545/577–613 nm, for TAMRA) and Alexa680 (λex/em = 650–675/700–730 nm, for the PageRuler Prestained NIR Protein Ladder (Thermo Scientific)) channels on a ChemiDoc MP Imaging System (Bio-Rad).

**Cellular activity-based protein profiling**

Cells (7 × 10⁴) were seeded in six-well plates and cultivated for 48 h. Cells were then incubated in fresh DMEM supplemented with compound or DMSO for 24 h. The cells were washed with ice-cold PBS and harvested in 200 µL ABP lysis buffer as described above. The cell lysate was diluted to a protein concentration of 2 mg/mL with ABP lysis buffer. One microliter of each click reagent (see above) were added to each sample, followed by an incubation period of one hour at room temperature. Samples were separated by SDS-PAGE and analyzed for fluorescent protein-compound conjugates as described above.

**Western blotting**

Proteins were transferred to a polyvinylidene fluoride (PVDF, only experiments in Fig. 4e and Supplementary Fig. 7e, f) or nitrocellulose (all other experiments) membrane using a Trans-Blot Turbo system (Bio-Rad, 1.3 A, 25 V, 10 min). The membranes were blocked with 5% (m/v) nonfat milk in PBS-T buffer and incubated with indicated primary antibodies (anti-UCHL1, 1:1000, Cell Signaling, D37E; anti-PARK7, 1:1000, Cell Signaling, D29ES; anti-Tubulin, 1:4000, Sigma, T6199; anti-HER2/neu, 1:1000, BioLegend, 16B12; anti-flag, 1:2000, Sigma, F3165; anti-Ubiquitin, 1:1000, Cell Signaling, P4D1; anti-Ubiquitin, 1:300, Santa Cruz, P4D1, sc-8017; anti-UCHL3, 1:1000, Proteintech, 12384-1-AP) overnight. Then the membranes were incubated with the respective secondary antibody (anti-mouse, 1:5000, Sigma, NA931; anti-rabbit, 1:5000, Sigma, GENA934) coupled to horseradish peroxidase. The chemiluminescent reaction was initiated using a Clarity Western ECL substrate (Bio-Rad) and Images were taken on a ChemiDoc MP Imaging System (Bio-Rad).

**Cellular Ub-probe competition**

Cells were cultured, treated with a compound, and lysed as described above. The total protein concentration was adjusted to 2 mg/mL by diluting each sample with ABP lysis buffer. A final concentration of 1 µM HA-Ub-VS probe was added, followed by incubation for 30 min at 37°C. The labeling reaction was quenched by the addition of 4X LDS sample buffer. The samples were separated by SDS-PAGE and further analyzed via western blotting as described above.

**Identification of probe-labeled proteins with mass spectrometry**

Cells were cultured, treated with a compound, and lysed as described above. The cell lysate was diluted to a protein concentration of 2 mg/mL with ABP lysis buffer. 1 µL of each click reagent (see above) were added to each sample, followed by an incubation period of one hour at room temperature with protection from light. The sample volume was adjusted to 1000 µL with PBS and 30 µL of a NeutrAvidin (Thermo Fisher) bead slurry (preshewed 3x with PBS) were added to each sample. The samples were incubated for one hour to overnight on a rotator at 15 rpm at 4°C. Beads were pelleted by centrifugation, the supernatant was discarded, and the beads were washed six times (1x with ½x lysis buffer, followed by five washes with PBS). After removing the washing solution completely, the beads were subjected to reduction with dithiothreitol (1 mM), alkylation with chloroacetamide (5 mM) and on-bead digestion with first LysC (Serva Biotech, 1h, 37°C), followed by trypsin (Sigma Aldrich, 1h, overnight). Tryptic peptides were desalted with C18 StageTips and analyzed by nano-HPLC-MS/MS.

An Ultimate 3000 RSLC nano-HPLC system and a Hybrid-Orbitrap mass spectrometer (Q Exactive Plus) equipped with a nano-spray source (Thermo Fisher Scientific) was used. The protein fragments were enriched on a C18 PepMap 100 column (5 µm, 100 Å, 300 µm ID × 5 mm, Dionex) using 0.1% TFA, at a flow rate of 30 µL/min, for 5 min and separated on a C18 PepMap 100 column (3 µm, 100 Å, 75 µm
with consistent results. Where possible, values were obtained as averages from multiple independent experiments as stated in the Figure legends.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

Data related to the structure of methylated UCHL1 in complex with GK135 have been deposited with the protein data bank under accession code 7ZM0. Proteomics data have been deposited with ProteomeXchange under accession codes MSV000090044 and MSV000090045. Chemical characterization data, as well as uncropped gels and blots, are provided in the Supplementary Information. All data were available on request from the authors. Protein sequences are available through the uniprot database under the following accession codes: UCHL1: P09936; UCHL3: P15374; UCHL5: Q9YSK5; BAPI: Q92560; and PARK7: Q99497. Source data are provided with this paper.

**References**

1. Clague, M. J., Urbe, S. & Komander, D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat. Rev. Mol. Cell Biol. **20**, 338–352 (2019).

2. Sahtoe, D. D. et al. Mechanism of UCH-L5 activation and inhibition by DEUBAD domains in RPN13 and INO80G. Mol. Cell **57**, 887–900 (2015).

3. Bishop, P., Rocca, D. & Henley, J. M. Ubiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunction. Biochem. J. **473**, 2453–2462 (2016).

4. Bilgic, V. et al. Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc. Natl Acad. Sci. USA **110**, 3489–3494 (2013).

5. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. **23**, 47–51 (1999).

6. Osaka, H. et al. Ubiquitin carboxy-terminal-hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. **12**, 1945–1958 (2003).

7. Reinicke, A. T. et al. Ubiquitin C-terminal hydrolase L1 (UCH-L1) loss causes neurodegeneration by altering protein turnover in the first postnatal weeks. Proc. Natl Acad. Sci. USA **116**, 7963–7972 (2019).

8. Chen, F., Sugiuira, Y., Myers, K. G., Liu, Y. & Lin, W. Ubiquitin carboxy-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction. Proc. Natl Acad. Sci. USA **107**, 1366–1371 (2010).

9. Liu, S. et al. Deubiquitination activity profiling identifies UCHL1 as a candidate oncoprotein that promotes TGFbeta-induced breast cancer metastasis. Clin. Cancer Res. **26**, 1460–1473 (2020).

10. Goto, Y. et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1alpha. Nat. Commun. **6**, 6153 (2015).

11. Bett, J. S. et al. Ubiquitin C-terminal hydrolases cleave isopeptide and peptide-linked ubiquitin from structured proteins but do not edit ubiquitin homopolymers. Biochem. J. **466**, 489–498 (2015).

12. Zhou, Z. R., Zhang, Y. H., Liu, S., Song, A. X. & Hu, H. Y. Length of the active-site crossover loop defines the substrate specificity of ubiquitin C-terminal hydrolases for ubiquitin chains. Biochem. J. **441**, 143–149 (2012).

13. Boudreaux, D. A., Maiti, T. K., Davies, C. W. & Das, C. Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl Acad. Sci. USA **107**, 9117–9122 (2010).
14. Das, C. et al. Structural basis for conformational plasticity of the Parkinson’s disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl Acad. Sci. USA 103, 4675–4680 (2006).
15. Larsen, C. N., Krantz, B. A. & Wilkinson, K. D. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37, 3358–3368 (1998).
16. Liu, Y., Fallon, L., Lashley, H. A., Liu, Z. & Lansbury, P. T. Jr The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111, 209–218 (2002).
17. Kyrtzis, E., Pavlaki, M. & Stefanis, L. The S18Y polymorphic variant of UCH-L1, with anti-oxidant function to neuronal cells. Hum. Mol. Genet. 17, 2160–2171 (2008).
18. Nakamura, T. et al. Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer’s disease. Science 371, eaaw0843 (2021).
19. Gopinath, P., Ohayon, S., Nawatha, M. & Brik, A. Chemical and semisynthetic approaches to study and target deubiquitinas. Chem. Soc. Rev. 45, 471–498 (2016).
20. Harrigan, J.A., Jacq, X., Martin, N.M. & Jackson, S.P. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 17, 57–78 (2017).
21. Weisberg, E. L. et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat. Chem. Biol. 13, 1207–1215 (2017).
22. Lange, S. M., Armstrong, L. A. & Kulathu, Y. Deubiquitinases: from mechanisms to their inhibition by small molecules. Mol. Cell 82, 15–29 (2022).
23. Ramirez, Y. A. et al. Structural basis of substrate recognition and covalent inhibition of Cdu1 from Chlamydia trachomatis. Chem. MedChem 13, 2014–2023 (2018).
24. Kemp, M., Stockley, M. & Jones, D. G. C. Cytanopyrrolidines as dual inhibitors for the treatment of cancer. US Patent 2018019472A1 (2018).
25. Jones, A. et al. Novel compounds. WO2016046530A1 (2016).
26. Krabill, A. D. et al. Ubiquitin C-terminal hydrolase-L1: biochemical and cellular characterization of a covalent cytanelpyrrolidine-based inhibitor. ChemBioChem 21, 712–722 (2020).
27. Panyain, N. et al. Discovery of a potent and selective covalent inhibitor and activity-based probe for the deubiquitylating enzyme UCH-L1, with antifibrotic activity. J. Am. Chem. Soc. 142, 12020–12026 (2020).
28. Panyain, N. et al. Activity-based protein profiling reveals deubiquitinasinase and aldehydehyrogenase targets of a cytanelpyrrolidine probe. RSC Med. Chem. 12, 1935–1943 (2021).
29. Kooij, R. et al. Small-molecule activity-based probe for monitoring ubiquitin C-terminal hydrolase L1 (UCH-L1) activity in live cells and zebrafish embryos. J. Am. Chem. Soc. 142, 16825–16841 (2020).
30. Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 e16 (2017).
31. Flohr, S. et al. 2-Cyano- pyridinidines and triazines as cysteine protease inhibitors. US patent 7006058B2 (2010).
32. Arnould, J.-C., Bird, T.G., Boyle, F.T. & Blakey, D.C. Indole derivatives with vascular damaging activity. US Patent 7,030,123 (2006).
33. Donato, N.J. et al. Deubiquitinase inhibitors and methods for use of the same. WO201504553A1 (2018).
34. Guedat, P. et al. Inhibitors of cysteine proteases, the pharmaceutic compositions thereof and their therapeutic applications. WO2007066200A3 (2007).
35. Jones, A., Kemp, M., Stockley, M., Gibson, K. & Whitlock, G. 1-Cyano pyridinidines compounds as USP30 inhibitors. WO2016158816A1 (2016).
36. Sanman, L. E. & Bogyo, M. Activity-based profiling of proteases. Annu. Rev. Biochem. 83, 249–273 (2014).
37. Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149–1159 (2002).
38. Pinto-Fernandez, A. et al. Comprehensive landscape of active deubiquitinating enzymes profiled by advanced chemoproteomics. Front. Chem. 7, 592 (2019).
39. Nodwell, M. B. & Sieber, S. A. ABPP methodology: introduction and overview. Top. Curr. Chem. 324, 1–41 (2012).
40. Tjaden, A. et al. Image-based annotation of chemogenomic libraries for phenotypic screening. Molecules 27, 1439 (2022).
41. Rut, W. et al. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 17, 222–228 (2021).
42. Meray, R. K. & Lansbury, P. T. Jr Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282, 10567–10575 (2007).
43. Liu, Y. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837–846 (2003).
44. Turnbull, A. P. et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550, 481–486 (2017).
45. Bishop, P., Rubin, P., Thomson, A. R., Rocca, D. & Henley, J. M. The ubiquitin C-terminal hydrolase L1 (UCH-L1) C terminus plays a key role in protein stability, but its farnesylation is not required for membrane association in primary neurons. J. Biol. Chem. 289, 36140–36149 (2014).
46. Kim, H. J. et al. N-terminal truncated UCH-L1 prevents Parkinson’s disease associated damage. PLoS ONE 9, e99654 (2014).
47. Raymert, I. Reductive alkylation of lysine residues to alter crystallization properties of proteins. Methods Enzymol. 276, 171–179 (1997).
48. Davies, C. W. et al. The co-crystal structure of ubiquitin carboxyterminal hydrolase L1 (UCH-L1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg. Med. Chem. Lett. 22, 3900–3904 (2012).
49. Johnston, S. C., Larsen, C. N., Cook, W. J., Wilkinson, K. D. & Hill, C. P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 A resolution. EMBO J. 16, 3787–3796 (1997).
50. Wang, Y. et al. Small molecule inhibitors reveal allosteric regulation of USP14 via steric blockade. Cell Res. 28, 1186–1194 (2018).
51. Gavory, G. et al. Discovery and characterization of highly potent and selective allosteric USP7 inhibitors. Nat. Chem. Biol. 14, 118–125 (2018).
52. Paez-Santos, Y. M. et al. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J. Med. Chem. 57, 2393–2412 (2014).
53. Rusilowicz-Jones, E. V. et al. USP30 sets a trigger threshold for PINK1-PARKIN amplification of mitochondrial ubiquitylation. Life Sci Alliance 3, e202000768 (2020).
54. Yang, J. et al. Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Leukemia 36, 210–220 (2022).
55. Winter, G. et al. DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D. Struct. Biol. 74, 85–97 (2018).
56. Tickle, I. J. et al. STARANISO (staraniso.globalphasing.org) (Global Phasing Ltd., 2018).
57. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658–674 (2007).
58. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486–501 (2010).
59. Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94–106 (2011).
60. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and
proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).

61. Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).

Acknowledgements
We thank the beamline scientists at the Swiss Light Source (SLS) for support during data collection and Raphael Gasper-Schönenbrücher for support with crystallization and biophysics. We are grateful for access to equipment and scientific advice from Daniel Rauh, Stefan Raunser, and Herbert Waldmann. We thank all staff at the Technical University and the Max Planck Institute for their excellent support. We are grateful to all members of the Gersch lab for discussions, advice, and reagents. This work was funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Project-ID GE 3110/1—Emmy Noether, to M.G.). Work in the Gersch lab is further supported by AstraZeneca, Merck KGaA, Pfizer Inc., and the Max Planck Society as part of the Chemical Genomics Center III (CGCIII-352S to M.G.) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Project-ID 424228829—SFB1430, to M.G.). We also acknowledge financial support by Deutsche Forschungsgemeinschaft and Technische Universität Dortmund/TU Dortmund University within the funding program Open Access Costs.

Author contributions
C.G., M.S., and G.-M.K. synthesized compounds. C.G. performed in vitro characterization and crystallization experiments. M.S. performed protein profiling, cellular target ID, and target validation experiments. R.O.D. performed cell viability measurements. K.G. with M.S. performed cellular characterization experiments. P.J. analyzed proteomics samples. All authors planned experiments and analyzed data. M.G. supervised the project and wrote the manuscript with input from all authors.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-33559-4.

Correspondence and requests for materials should be addressed to Malte Gersch.

Peer review information Nature Communications thanks Benedikt Kessler and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022